Clinical Trial Update: A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure [Phase 2]

View source ↗

Summary

A Phase 2a dose-ranging trial evaluating 6-hour IV doses of CXL-1427 in hospitalized heart failure patients has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure
• Heart Failure

Drugs mentioned

• CXL-1427

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Heart Failure, Decompensated Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2019-05-20